<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01835613</url>
  </required_header>
  <id_info>
    <org_study_id>AR/BIOM</org_study_id>
    <nct_id>NCT01835613</nct_id>
  </id_info>
  <brief_title>Evaluation Effects of Treatment With IL-6R Inhibitor on Clinical Response and Biomarkers in Patients With Rheumatoid Arthritis (RA) Not Responding to DMARDs and/or a First Biological Agent.</brief_title>
  <official_title>Evaluation Effects of Treatment With IL-6R Inhibitor on Clinical Response and Biomarkers in Patients With Rheumatoid Arthritis (RA) Not Responding to DMARDs and/or a First Biological Agent.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Osservatorio Epidemiologico GISEA</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Osservatorio Epidemiologico GISEA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the clinical response to IL-6 inhibition defined as
      Low Disease Activity (DAS44) &lt;2.4) at the follow-up visit at 12 months and the correlation
      between the biomarkers and treatment response.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease Activity Score (DAS-44)</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Simplified Disease Activity Index (SDAI);Biomarkers Measures</measure>
    <time_frame>SDAI at 3-6-12-18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers Measures</measure>
    <time_frame>Biomarkers Measures at 3-6-12-18 months</time_frame>
    <description>Evaluation by ELISA of the levels of the following biomarkers:
IL-8, MCP-1, Chemerin, IL-1α, IL-1β, IL-17, IL-23, TGFβ1, IL-10, BAFF.in the plasma:</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Rheumatoid Arthritis (RA)</condition>
  <arm_group>
    <arm_group_label>Tocilizumab</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Biomarkers Measures
At the routine visits (0, 3, 6, 12 and 18 months), a clinical evaluation will be made and samples collected for assaying the biomarkers.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Biomarkers Measures</intervention_name>
    <description>At the routine visits (0, 3, 6, 12 and 18 months), a clinical evaluation will be made and samples collected for assaying the biomarkers.</description>
    <arm_group_label>Tocilizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Signed informed consent form;

          -  Patients aged 18 - 75 years;

          -  RA classified in compliance with the 2010 ACR/EULAR criteria;

          -  Patients that have to suspend a previous treatment with DMARDs for total
             ineffectiveness or intolerance to drugs and/or patients that have not responded
             adequately to first-line combination DMARDs / biological treatment;

          -  Patients for which is indicated to start a treatment with an inhibitor of IL-6R for
             high values indicative of systemic inflammation (ESR&gt;=28 mm/hour, PCR&gt;5 mg/l ,
             Fibrinogen &gt;400 mg/dl and or Albumin &lt;3.5 g/dl) and high disease activity (DAS&gt;2.4),
             or contraindications to DMARDs use which make it necessary to take biological drug in
             monotherapy.

          -  Corticosteroids therapy stable (&lt; = 7.5 mg)for at least four weeks;

          -  Joint symptoms for at least three but no more than 24 months from the screening visit;

          -  DAS44 &gt;2.4 and/or SDAI &gt;11

          -  Willing and able to comply with study procedures and timing.

        Exclusion criteria:

          -  On going pregnancy or lactation;

          -  Severe active infections;

          -  Patients with other clinically significant concomitant diseases whose treatment or
             outcome could interfere with the expected evaluations of the study protocol.

          -  Blood AST or ALT levels &gt;5 times the upper normal limit;

          -  ANC count &lt;0.5 x 109/L

          -  Platelet count &lt;50 x103 /μL

          -  Patients with other autoimmune rheumatic diseases, in addition to AR (for example
             systemic lupus erythematosus [SLE], scleroderma, polymyositis, ecc…)

          -  Medical history or concomitant joint diseases in additions to AR (for example
             tophaceous gout, reactive arthritis, psoriatic arthritis).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gianfranco Ferraccioli, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dipartimento di Reumatologia, Università Cattolica del Sacro Cuore, Roma</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Giovanni Lapadula, Prof.</last_name>
    <phone>+39 080 5478866</phone>
    <email>info@oegisea.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Università Cattolica del Sacro Cuore</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 1, 2013</study_first_submitted>
  <study_first_submitted_qc>April 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 19, 2013</study_first_posted>
  <last_update_submitted>April 18, 2013</last_update_submitted>
  <last_update_submitted_qc>April 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 19, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rheumatoid Arthritis</keyword>
  <keyword>Early RA</keyword>
  <keyword>RA</keyword>
  <keyword>IL-6</keyword>
  <keyword>IL-6R</keyword>
  <keyword>Inhibitor</keyword>
  <keyword>Inhibition</keyword>
  <keyword>Tocilizumab</keyword>
  <keyword>Biomarkers</keyword>
  <keyword>DMARDs</keyword>
  <keyword>Biological</keyword>
  <keyword>DAS</keyword>
  <keyword>SDAI</keyword>
  <keyword>AR/BIOM</keyword>
  <keyword>OEG</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

